Mesoblast Eyes FDA Approval and Extends Patent Portfolio
Company Announcements

Mesoblast Eyes FDA Approval and Extends Patent Portfolio

Mesoblast (MESO) has released an update.

Mesoblast Limited announced its plans to file for FDA approval for Ryoncil, a treatment for acute graft versus host disease, with potential market entry in the second half of 2024. The company also highlighted ongoing Phase 3 programs for heart failure and back pain, and its strong U.S. intellectual property position, with patents potentially extending through 2043. Mesoblast is a global leader in allogeneic cellular medicines, with a broad portfolio targeting severe inflammatory conditions and a robust global intellectual property portfolio.

For further insights into MESO stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMesoblast Poised for Breakthroughs in Cellular Medicine
TheFlyMesoblast management to meet with Maxim
TipRanks Auto-Generated NewsdeskMesoblast Advances Cellular Medicines Amid FDA Hopes
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App